BBIO vs BLTE Stock Comparison

BLTE currently leads BBIO in this stock comparison, with AIQ scores of 74 vs 64. The clearest difference is quality.

Market data as of Nov 15, 2026 market close· AIQ score gap 10 points
BBIO
Healthcare
vs
BLTE
Healthcare
BBIO
BridgeBio Pharma, Inc.
Price
$78.30
Day move
+0.17%
AIQ Score
64/100
Best edge
Balanced
Sector
Healthcare
BLTE
Belite Bio, Inc
Leads
Price
$164
Day move
-3.3%
AIQ Score
74/100
Best edge
Quality
Sector
Healthcare

What is the main difference between BBIO and BLTE?

BLTE leads the current stock comparison as Belite Bio, Inc, with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

BridgeBio Pharma, Inc. vs Belite Bio, Inc

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 4/10

BLTE leads

BLTE leads by 10 AIQ points, primarily on Quality, but the lead has narrowed from 22 points over 30 sessions.

Fragile: 2 of 5 evidence groups support BLTE, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 2 of 5Comparison trend: Weakening
BBIO

BridgeBio Pharma, Inc.

AIQ Score
64/100
AIQ Edge Score
7/10
BLTE

Belite Bio, Inc

Leads
AIQ Score
74/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors BLTE over BBIO, 74 versus 64 as of Nov 15, 2026. BLTE's advantage is driven primarily by stronger quality. BLTE also shows the weaker technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor BLTE today, and the comparison is rated Fragile on stability: only 2 of 5 covered evidence groups agree. BLTE lead: Weakening — the AIQ differential moved from 22 to 10 points over 30 sessions.

Compare BridgeBio Pharma, Inc. and Belite Bio, Inc across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

BBIO
+876.3%
BLTE
+1452.0%

Price return comparison

Growth of $10,000, price only

BBIO $97,631 · BLTE $155,198

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare BBIO and BLTE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BBIO advantage
0
BLTE advantage
  • Quality66 vs 85
    BLTE +19
  • Momentum69 vs 71
    Even
  • Risk Resilience62 vs 60
    Even

2 of 5 evidence groups favor BLTE. BLTE’s edge is concentrated in quality.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

BBIO+1 AIQ

Largest factor move: Quality +1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

BLTE+1 AIQ

Largest factor move: Momentum +4

New signals

  • RSI Bearish Divergence — bearish, momentum, medium horizon

BLTE's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — BBIO and BLTE both carry a full feed there.

The central trade-off

BLTE (Belite Bio, Inc): the stronger current systematic profile, led by quality.

BBIO (BridgeBio Pharma, Inc.): the counter-case, on fundamentals, technicals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BLTE

BLTE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BBIO

BBIO on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

Even

The two are level on Momentum.

Lower downside

BBIO

BBIO carries the lower 1-month annualized volatility.

Analyst upside

BLTE

BLTE on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBBIOBLTENote
Implied upside to target+42%+58.6%BLTE has more room
Target dispersion+62.1%+26.5%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering229Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor BLTE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBLTE64 vs 74
FundamentalsBBIOEPS growth 46.2% vs -5.6%
ValuationNot coveredNot covered
TechnicalsBBIOPrice vs 50-day 11.9% vs 2.2%; vs 200-day 7.7% vs 2.7%
Risk ResilienceEvenRisk Resilience 62 vs 60
Analyst expectationsBLTETarget upside 42% vs 58.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BBIO and BLTE and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 10 points.
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BLTE.

How the comparison changed

45 daily snapshots · Sep 14 – Nov 13

BLTE lead: Weakening — the AIQ differential moved from 22 to 10 points over 30 sessions.

Sep 14BBIO leads above the line · BLTE leads belowNov 13
Today
BLTE +10
64 vs 74
7 sessions ago
BLTE +10
62 vs 72
30 sessions ago
BLTE +22
50 vs 72
90 sessions ago
Not covered

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BBIOConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BBIO

  • Death Cross Active — bearish, trend, long horizon (3.88%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
  • TRIX Bullish Signal — bullish, momentum, short horizon
BLTEConflicted

5 bullish / 1 bearish / 1 neutral, conflicted

Only BLTE

  • Golden Cross Active — bullish, trend, long horizon (0.48%)
  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.07%)
  • Accumulation Pattern — bullish, volume, medium horizon (1.24x)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • RSI Bearish Divergence — bearish, momentum, medium horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 1 more signal that do not separate them: EMA Ribbon Expansion Bullish.

BLTE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).

BLTEDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -3.3%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BBIO closes the Quality gap — currently 19 points behind, the largest single contributor to BLTE's edge.
  2. 2BBIO's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3BLTE's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 10-point move would eliminate BLTE's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BBIO leads on balance
MetricBBIOBLTE
Revenue growth (YoY)44.9%0%
EPS growth (YoY)46.2%-5.6%
Gross margin93.5%0%
Operating margin-43.4%0%
Return on equity (TTM)3.4%0%
Debt to equity-1.50

Performance

BLTE leads 4 of 6 windows
MetricBBIOBLTE
1 week (5 sessions)5.4%6.6%
1 month (20 sessions)17.9%15.1%
3 months (63 sessions)-2%0.7%
6 months (126 sessions)18.4%14.9%
Year to date2.4%2.7%
1 year (252 sessions)18.2%48.3%

Technicals

BBIO has the stronger structure
MetricBBIOBLTE
RSI (14)6557.3
ADX (14)38.919.3
Price vs 50-day11.9%2.2%
Price vs 200-day7.7%2.7%
Volatility (1M, annualized)39.1%59%

Risk

Split
MetricBBIOBLTE
Beta0.951.05
Sharpe ratio0.550.9
Sortino ratio0.841.46
Max drawdown-29.8%-29.1%
Current drawdown-13.2%-15.1%
Annualized volatility44.1%53.7%
Value at risk (95%)-4%-4.7%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BBIO or BLTE?

On the Algovestiq AIQ Score, BLTE is the stronger of the two as of Nov 15, 2026, scoring 74 against BBIO's 64. The edge comes from quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BBIO or BLTE the better buy right now?

BLTE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 5 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor BLTE over BBIO?

The composite weights Quality, Value, Momentum and Risk Resilience. BLTE leads Quality by 19 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BBIO or BLTE?

Analyst price targets imply +42% upside for BBIO and +58.6% for BLTE, so the Street currently favors BLTE. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BBIO or BLTE?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BBIO or BLTE?

BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BBIO or BLTE?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BBIO or BLTE?

BBIO is the more resilient of the two, so the other name carries the higher downside risk. BBIO carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BBIO more profitable than BLTE?

Margin data is not comparable for both names in the current snapshot.

Is BLTE's lead over BBIO getting stronger or weaker?

BLTE lead: Weakening — the AIQ differential moved from 22 to 10 points over 30 sessions. This is measured from 45 daily comparison snapshots between 2026-09-14 and 2026-11-13. The lead has not changed hands in that window.

What would change the BBIO vs BLTE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BBIO closes the Quality gap — currently 19 points behind, the largest single contributor to BLTE's edge; BBIO's Death Cross Active resolves — a bearish trend rule currently active against it; BLTE's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 10-point move would eliminate BLTE's advantage entirely.

What do the current signals say about BBIO and BLTE?

BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. BLTE: 5 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BBIO is Death Cross Active (bearish, long horizon). On BLTE it is Golden Cross Active (bullish, long horizon).

Compare BBIO and BLTE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.